Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cabozantinib + temozolomide
- Development stage
- Unknown
- Lead developer
- Northwestern University
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination therapy consisting of cabozantinib, a multi-tyrosine kinase inhibitor targeting VEGFR2, MET, AXL, RET, KIT, FLT3, and TIE-2, and temozolomide, an alkylating agent that damages DNA in cancer cells. This combination has demonstrated synergistic anticancer effects in preclinical studies and clinical trials, particularly for soft tissue sarcomas including leiomyosarcoma. The dual targeting of VEGF and c-MET pathways with cabozantinib, combined with temozolomide's DNA-damaging effects, produces a synergistic antitumor effect.
02
Targets
AXL (AXL receptor tyrosine kinase)MET (Mesenchymal-epithelial transition factor receptor)TEK (Tie2)DNAVEGFR2 (Vascular endothelial growth factor receptor 2)RET (Rearranged during transfection receptor tyrosine kinase)FLT3 (Fms related receptor tyrosine kinase 3)KIT (c-KIT proto-oncogene receptor tyrosine kinase)
Beyond the preview
Go deeper on cabozantinib + temozolomide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cabozantinib + temozolomide.